Skip to content
yes i take peptides.
Library/For Weight Loss/Liraglutide
FDA ApprovedGLP-1+2 more

Liraglutide

The original FDA-approved GLP-1 for weight loss. We read all 60 studies. The protocol is below.

Updated 20 May 2026Read 10 minEvidence ●●●●●Citations 60
+ Add to Stack
⚖ Compare side-by-side⎙ Print companion card

Free — puts Liraglutide on your decision board.

The Liraglutide Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status
FDA
Class
GLP-1
Evidence
5/ 5●●●●●
FDA approval (Saxenda)
Dec 2014
Phase 3 weight loss
$19 ↓
SCALE enrollment
$19 ↓
Read this if
  • you have a teenager 12+ with obesity and Saxenda is on the table — it's the only on-label GLP-1 for that age
  • you're a parent of a 12–17-year-old whose pediatric endocrinologist mentioned liraglutide — it's the only on-label GLP-1 for that age group (Saxenda, ages 12+ for obesity). Daily injection, supervised under endocrinology, not a shortcut around teen-specific lifestyle work
  • you're cost-sensitive and the new generic is finally affordable
  • you couldn't tolerate semaglutide's GI profile and want to step down to a shorter half-life
Skip this if
  • you can tolerate a weekly injection — the weeklies hit harder and hurt your routine less
  • you have a personal or family history of medullary thyroid carcinoma or MEN-2
  • you have a history of pancreatitis
The 4 ways you can buy Liraglutide
Brand
✓
FDA-approved
$469–$1,349/mo (Hikma Victoza generic to Saxenda retail)
Real pharmacy product. Three SKUs: Hikma generic Victoza (T2D) ~$469 cash; Teva generic Saxenda (w…
Compounded 503A
⚠
Prescription
$165–$500/mo
Pharmacy-grade — but most compounders pulled liraglutide after shortage ended.
RUO (research-only)
✓
Sold 'for research only'
$300–$1,000/mo at full 3mg/d dose
No purity guarantee. Daily 3mg dose × 30 days makes RUO liraglutide more expensive than gray and r…
Gray market
✓
Unregulated overseas import
Varies — not on user's vendor list
Available via overseas raws but daily-dose math (90mg/mo) makes liraglutide a poor gray-market can…
Click any lane for the full Sourcing breakdown.
First 90 days · Liraglutide
Weeks 1–2
GI side effects start. Nausea is the rate-limiter. Don't titrate up if you can't tolerate the starting dose — the side-effect curve gets steeper, not flatter.
Weeks 4–8
Appetite suppression becomes the obvious effect. 1–2 lbs/week is typical. Hit a plateau? Hold the dose, don't immediately bump.
Week 12 — decide
Bloodwork: A1c, lipids, liver enzymes, fasting insulin. Visible weight change should be 5–10%. If the trajectory is flat at 12 weeks and you've titrated, this isn't your molecule.
Quit if
  • Pancreatitis-like pain (severe upper-abdominal, won't sit still): stop and call your doctor.
  • Gallbladder pain or persistent vomiting that won't resolve.
  • Severe muscle loss without resistance training (the 'GLP-1 face' is real — protein floor matters).
  • 12 weeks at full dose with zero weight movement (rare, but real).
Identity

What it is.

Liraglutide is the original modern GLP-1 agonist. Novo Nordisk approved it for type 2 diabetes in 2010 (as Victoza) and for weight management in 2014 (as Saxenda). Same molecule, different label.

The molecular engineering is older — a single fatty-acid chain attached to the native sequence to slow enzymatic breakdown. It works for about 24 hours, which is why it's daily, not weekly.

It's been mostly displaced by semaglutide and tirzepatide for new starts, but it still has a real role: it's now off-patent, generic versions are arriving, and it's the only with FDA approval down to age 12 for pediatric obesity.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Liraglutide actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓
Mechanism

Mechanism.

Mechanism · in the Liraglutide report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓
Evidence

Evidence. What we actually know in humans.

Evidence · in the Liraglutide report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓
Human-Evidence Factbox
FDA approval (Saxenda)
Dec 2014
Phase 3 weight loss
$19 ↓
SCALE enrollment
$19 ↓
Dosing
$19 ↓
Pediatric approval
$19 ↓
Generic (Victoza, T2D)
$19 ↓
Generic (Saxenda, weight loss)
$19 ↓
Dose

Dose. The actual protocol.

Dose · in the Liraglutide report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.
Get the report · $19 ↓
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Liraglutide report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.
Get the report · $19 ↓
Safety

Safety. Side effects.

Safety · in the Liraglutide report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓
Editorial Position

Editorial position.

Editorial Position · in the Liraglutide report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓
Citations

Citations.

  1. 01Guo T, et al. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Molecular medicine (Cambridge, Mass.). 2023;29(1):132. PMID: 37770820.
  2. 02Secher A, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. The Journal of clinical investigation. 2014;124(10):4473-88. PMID: 25202980.
  3. 03Ni XY, et al. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta pharmacologica Sinica. 2024;45(8):1604-1617. PMID: 38589689.
  4. 04Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & metabolism. 2020;46(2):100-109. PMID: 31539622.
  5. 05Blackman A, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. International journal of obesity (2005). 2016;40(8):1310-9. PMID: 27005405.
+Show all 60 citations
  1. 06Carlsson Petri KC, et al. Liraglutide pharmacokinetics and exposure-response in adolescents with obesity. Pediatric obesity. 2021;16(10):e12799. PMID: 33963681.
  2. 07Meurot C, et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Scientific reports. 2022;12(1):1567. PMID: 35091584.
  3. 08Pandey A, et al. Liraglutide innovations: a comprehensive review of patents (2014-2024). Pharmaceutical patent analyst. 2024;13(1-3):73-89. PMID: 39316579.
  4. 09Takahashi T, et al. [Liraglutide]. Nihon rinsho. Japanese journal of clinical medicine. 2011;69(5):883-9. PMID: 21595276.
  5. 10Zhang K, et al. Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE (-/-) mice. Biochemical pharmacology. 2024;223:116170. PMID: 38548245.
  6. 11Mathieu C, et al. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes care. 2016;39(10):1702-10. PMID: 27506222.
  7. 12Gupta P, et al. Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers. Current drug research reviews. 2024;16(3):289-299. PMID: 37966282.
  8. 13Nylander M, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reproductive biomedicine online. 2017;35(1):121-127. PMID: 28479118.
  9. 14Mikhail N. Cardiovascular Effects of Liraglutide. Current hypertension reviews. 2019;15(1):64-69. PMID: 29737256.
  10. 15Chen Z, et al. GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice. The Journal of clinical investigation. 2024;134(17). PMID: 39225090.
  11. 16Camkurt MA, et al. Liraglutide for psychiatric disorders: clinical evidence and challenges. Hormone molecular biology and clinical investigation. 2018;36(2). PMID: 30020885.
  12. 17Gammoh O, et al. Metabolic resilience: liraglutide's potential in alleviating depressive symptoms. Molecular biology reports. 2025;52(1):550. PMID: 40471368.
  13. 18Madsbad S. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. Expert review of cardiovascular therapy. 2019;17(5):377-387. PMID: 31055989.
  14. 19Wiseman S. Liraglutide and learning. Nature neuroscience. 2023;26(10):1660. PMID: 37789197.
  15. 20Alsanea S, et al. Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2024;30(8):737-745. PMID: 38782201.
  16. 21Shyangdan D, et al. Liraglutide for the treatment of type 2 diabetes. Health technology assessment (Winchester, England). 2011;15 Suppl 1:77-86. PMID: 21609656.
  17. 22McElroy SL, et al. Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder. Journal of clinical psychopharmacology. 2024;44(2):89-95. PMID: 38227621.
  18. 23Zhao M, et al. Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion. Reproductive biology and endocrinology : RB&E. 2024;22(1):98. PMID: 39107809.
  19. 24Gao G, et al. Liraglutide attenuates doxorubicin-induced cardiomyocyte ferroptosis via DHHC7-mediated STAT3 palmitoylation. Life sciences. 2025;379:123912. PMID: 40819789.
  20. 25Sun Z, et al. Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation. International immunopharmacology. 2024;142(Pt B):113258. PMID: 39340991.
  21. 26Tian D, et al. Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis. Minerva medica. 2022;113(3):542-550. PMID: 33555153.
  22. 27Dejgaard TF, et al. Liraglutide for treating type 1 diabetes. Expert opinion on biological therapy. 2016;16(4):579-90. PMID: 26926662.
  23. 28Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015;75(8):899-910. PMID: 25985864.
  24. 29Nuffer WA, et al. Liraglutide: A New Option for the Treatment of Obesity. Pharmacotherapy. 2015;35(10):926-34. PMID: 26497479.
  25. 30Wiciński M, et al. Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events. International journal of molecular sciences. 2019;20(5). PMID: 30823403.
  26. 31Manigault KR, et al. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2016;31(12):685-697. PMID: 28074747.
  27. 32Aguilar Salinas CA, et al. Liraglutide in Prader Willi-Syndrome: The Importance of Placebo-Controlled Studies. The Journal of clinical endocrinology and metabolism. 2023;108(7):e493-e494. PMID: 36638011.
  28. 33Kalogirou MS, et al. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clinics and research in hepatology and gastroenterology. 2021;45(3):101568. PMID: 33309563.
  29. 34Iepsen EW, et al. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert review of cardiovascular therapy. 2015;13(7):753-67. PMID: 26106933.
  30. 35Zhao D, et al. Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Clinical and experimental hypertension (New York, N.Y. : 1993). 2020;42(5):393-400. PMID: 31610701.
  31. 36Clements JN, et al. Liraglutide: an injectable option for the management of obesity. The Annals of pharmacotherapy. 2015;49(8):938-44. PMID: 25986009.
  32. 37Mali N, et al. Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. BMC endocrine disorders. 2022;22(1):93. PMID: 35392872.
  33. 38Korkmaz H, et al. Liraglutide-related cholelithiasis. Aging clinical and experimental research. 2015;27(5):751-3. PMID: 25725635.
  34. 39Ladenheim EE. Liraglutide and obesity: a review of the data so far. Drug design, development and therapy. 2015;9:1867-75. PMID: 25848222.
  35. 40— ▾ Liraglutide for weight management. Drug and therapeutics bulletin. 2017;55(7):78-81. PMID: 28701318.
  36. 41Jacobsen LV, et al. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. Clinical pharmacokinetics. 2016;55(6):657-72. PMID: 26597252.
  37. 42Fang J, et al. Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats. Brain research bulletin. 2023;192:142-155. PMID: 36410565.
  38. 43Sisson EM. Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy. 2011;31(9):896-911. PMID: 21923591.
  39. 44Li Y, et al. Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway. Life sciences. 2025;360:123267. PMID: 39608448.
  40. 45Xu Q, et al. Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway. Journal of diabetes and its complications. 2025;39(3):108975. PMID: 39987624.
  41. 46Christou GA, et al. The Current Role of Liraglutide in the Pharmacotherapy of Obesity. Current vascular pharmacology. 2016;14(2):201-7. PMID: 26074046.
  42. 47Vilsboll T. Liraglutide: a new treatment for type 2 diabetes. Drugs of today (Barcelona, Spain : 1998). 2009;45(2):101-13. PMID: 19343230.
  43. 48Greig SL, et al. Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes. Drugs. 2015;75(13):1523-34. PMID: 26242767.
  44. 49Croom KF, et al. Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs. 2009;69(14):1985-2004. PMID: 19747013.
  45. 50Schmidt PHS, et al. Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review. Obesity research & clinical practice. 2025;19(1):11-18. PMID: 39904668.
  46. 51Zhang L, et al. Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-κb pathways. Scientific reports. 2025;15(1):27274. PMID: 40715315.
  47. 52He F, et al. Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes, obesity & metabolism. 2023;25(3):664-674. PMID: 36314246.
  48. 53Rotella JA, et al. Liraglutide toxicity presenting to the emergency department: A case report and literature review. Emergency medicine Australasia : EMA. 2019;31(5):895-896. PMID: 31304652.
  49. 54Chatterjee R, et al. Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus. Drug delivery and translational research. 2025;15(12):4479-4500. PMID: 40914786.
  50. 55Webster CM, et al. Potential contributors to variation in weight-loss response to liraglutide. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2023;24(7):e13568. PMID: 37069131.
  51. 56Li SL, et al. Liraglutide Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating Macrophage Polarization. Frontiers in immunology. 2022;13:869050. PMID: 35450076.
  52. 57Chan JSF, et al. Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner. The Journal of endocrinology. 2024;262(2). PMID: 38860519.
  53. 58Luo C, et al. The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies. African health sciences. 2022;22(3):267-274. PMID: 36910413.
  54. 59Caruso P, et al. Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial. Diabetes, obesity & metabolism. 2025;27(7):3891-3900. PMID: 40276845.
  55. 60Du Q, et al. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Advances in therapy. 2014;31(11):1182-95. PMID: 25388240.
The Liraglutide Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →